Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma

被引:14
|
作者
Yang, Jie [1 ]
Shen, Keng [1 ]
Wang, Jinhui [1 ]
Yang, Jiaxin [1 ]
Cao, Dongyan [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, 1 Shuaifuyuan, Beijing 100730, Peoples R China
关键词
Adjuvant Extrafascial Hysterectomy; Chemoradiotherapy; Locally Advanced Cervical Adenocarcinoma; Survival; CHEMORADIATION THERAPY; NEOADJUVANT CHEMOTHERAPY; CANCER; CARCINOMA; SURGERY; TRIAL;
D O I
10.3802/jgo.2016.27.e40
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To evaluate whether adjuvant simple hysterectomy after concurrent chemoradiotherapy (CCRT) improves progression-free survival (PFS) compared with current standard care in locally advanced cervical adenocarcinoma (LACAC). Methods: We reviewed a cohort of 55 patients with LACAC (International Federation of Gynecology and Obstetrics [FIGO] stage IB2, IIA2, IIB, III without distant metastasis) diagnosed and treated with radical CCRT at Peking Union Medical College Hospital between January 2004 and October 2014. We compared 34 patients who underwent adjuvant extrafascial hysterectomy with 21 patients with standard care after CCRT. The primary outcome was PFS. Overall survivals (OS) between the two groups were also compared. Surgery feasibility, operative complications, and pathologic features after radiation therapy were also analyzed. Results: PFS was significantly improved in surgery group (log-rank p=0.0097; hazard ratio [HR], 0.3431; 95% CI, 0.152 to 0.772), as were OS (log-rank p=0.0419; HR, 0.3667; 95% CI, 0.139 to 0.964). Analysis of stage IIB demonstrates a similar result. There were no severe complications related to postradiation surgery in this series. The mean blood loss was less in laparoscopic group than those in the open group (87 mL vs. 208 mL, p=0.036, Mann-Whitney U-test). Approximately 47% patients (16/34) had pathologic residue tumor on hysterectomy specimens. About 94% patients (32/34) got complete remission after adjuvant surgery. Conclusion: Adjuvant hysterectomy after CCRT improves survival outcome for patients with LACAC compared with current standard care. Extrafascial hysterectomy is sufficient in tumor reduction and laparoscopic procedure may be more promising with lower blood loss and expedite recovery.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Predictive Value of EGFR Mutation in Locally Advanced Adenocarcinoma of the Lung Treated with Concurrent Chemoradiotherapy
    Akamatasu, Hiroaki
    Kaira, Kyoichi
    Murakami, Haruyasu
    Ono, Akira
    Tsuya, Asuka
    Nakamura, Yukiko
    Kennmotsu, Tomotsugu
    Naito, Tateaki
    Takahashi, Toshiaki
    Harada, Hideyuki
    Endo, Masahiro
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S400 - S400
  • [42] Place of surgery before and after concurrent chemoradiotherapy for locally advanced cervical carcinoma: A retrospective study of 102 cases
    Lavoue, V.
    Voguet, L.
    Bertel, C.
    Mesbah, H.
    Williaume, D.
    Laguerre, B.
    Poree, P.
    Foucher, F.
    Montpetit, E.
    Leblanc, M.
    Leveque, J.
    JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION, 2011, 40 (01): : 11 - 21
  • [43] Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
    Byun, Sang Jun
    Kim, Jin Hee
    Kim, Ok Bae
    Song, Hong Suk
    RADIATION ONCOLOGY JOURNAL, 2011, 29 (01): : 20 - 27
  • [44] Comparison of Induction Chemotherapy plus Concurrent Chemoradiotherapy versus Concurrent Chemoradiotherapy alone in Locally Advanced Cervical Cancer Treated with IMRT and Concurrent Cisplatin
    Chen, S.
    Wang, X.
    Feng, J. C.
    Wei, M.
    Chen, G.
    Yin, P.
    Huang, H.
    Zhang, Y.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E480 - E480
  • [45] Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
    Jing Liu
    Guyu Tang
    Qin Zhou
    Weilu Kuang
    Radiation Oncology, 17
  • [46] Optimal cisplatin cycles in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy
    Zeng, Zheng
    Wang, Weiping
    Liu, Xiaoliang
    Wang, Guangyu
    Ren, Kang
    Zhang, Fuquan
    Hu, Ke
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2023, 25 (10): : 2892 - 2900
  • [47] CONCURRENT CHEMORADIOTHERAPY WITH HIGH-DOSE-RATE BRACHYTHERAPY FOR LOCALLY ADVANCED CERVICAL CANCER
    Kim, Y. S.
    Kim, J. H.
    Lee, S. W.
    Yoon, S. M.
    Ahn, S. D.
    Choi, E. K.
    RADIOTHERAPY AND ONCOLOGY, 2011, 99 : S310 - S310
  • [48] Outcomes and prognostic factors in patients with locally advanced cervical cancer treated with concurrent chemoradiotherapy
    Liu, Jing
    Tang, Guyu
    Zhou, Qin
    Kuang, Weilu
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [49] Phase II study of tislelizumab combined with concurrent chemoradiotherapy for locally advanced cervical cancer
    Ma, Shanshan
    Zhang, Yong
    Wu, Fang
    Jiang, Li
    Zhang, Tingting
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Optimal Cisplatin Cycles in Locally Advanced Cervical Carcinoma Patients Treated with Concurrent Chemoradiotherapy
    Zeng, Z.
    Zhang, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : E559 - E559